Product image of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) supplied by GNH India

Mircera

Active Ingredient:
Methoxy Polyethylene Glycol-Epoetin Beta
Origin:
EU

Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)

Methoxy Polyethylene Glycol‑Epoetin Beta, the active ingredient in Mircera, is an erythropoiesis‑stimulating agent presented as a solution for injection for intravenous or subcutaneous use. It treats anemia associated with chronic kidney disease in patients both on dialysis and not on dialysis.
GNH India supplies Mircera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Roche Registration Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mircera is an erythropoiesis‑stimulating agent indicated for anemia related to chronic kidney disease.

  • Anemia in CKD patients on dialysis: raises hemoglobin levels and reduces the need for blood transfusions.
  • Anemia in CKD patients not on dialysis: supports erythropoiesis to maintain target hemoglobin concentrations.
  • Anemia in CKD patients receiving erythropoietin‑stimulating therapy: provides long‑acting control of hemoglobin and improves quality of life.

How It Works

  • Methoxy Polyethylene Glycol‑Epoetin Beta binds to the erythropoietin receptor on erythroid progenitor cells in the bone marrow, activating intracellular JAK2/STAT5 signaling pathways. This stimulation promotes proliferation and differentiation of red‑cell precursors, leading to increased red blood cell production and higher circulating hemoglobin levels.

Side Effects

Mircera may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Hypertension: elevated blood pressure requiring monitoring.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Injection site reaction: redness, swelling, or discomfort at the administration site.

Serious or Rare Side Effects

  • Thromboembolic events: clot formation in veins or arteries.
  • Pure red cell aplasia: severe reduction in red blood cell production.
  • Anaphylaxis: acute allergic reaction with potential airway compromise.
  • Myocardial infarction: rare occurrence of heart attack.

Precautions & Warnings

Before initiating Mircera, clinicians should consider several safety measures.

  • Monitor hemoglobin: avoid rapid increases above target levels.
  • Assess cardiovascular risk: patients with hypertension need close observation.
  • Screen for iron deficiency: ensure adequate iron stores prior to therapy.
  • Avoid use in uncontrolled hypertension: may exacerbate blood pressure.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mircera can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Concurrent high‑dose iron dextran: increased risk of hypersensitivity.
  • Combination with other erythropoiesis‑stimulating agents: may cause excessive hemoglobin rise.
  • Use with uncontrolled hypertension medications: may worsen blood pressure.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: may affect blood pressure response.
  • Antiplatelet agents: monitor for altered bleeding risk.

Frequently Asked Questions

Mircera is prescribed to treat anemia in patients with chronic kidney disease, both those receiving dialysis and those who are not. By stimulating red blood cell production, it helps maintain adequate hemoglobin levels and reduces the need for blood transfusions.

The active ingredient binds to erythropoietin receptors on bone‑marrow progenitor cells, activating the JAK2/STAT5 signaling cascade. This promotes the proliferation and maturation of red‑cell precursors, leading to increased red blood cell formation and higher hemoglobin concentrations.

The dosing regimen for Mircera is individualized. A qualified prescriber determines the appropriate dose and administration schedule based on the patient’s hemoglobin level, weight, dialysis status, and response to therapy.

Safety data for Mircera in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Mircera product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mircera is a long‑acting, pegylated form of epoetin that allows less frequent dosing compared with conventional epoetin alfa or beta products. This can improve convenience and adherence while delivering comparable efficacy in raising hemoglobin levels.

Mircera should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution before use.

Mircera is supplied as a sterile solution for injection and can be given either intravenously or subcutaneously. Administration is performed by a qualified healthcare professional following aseptic technique.

Serious risks include hypertension, thromboembolic events, pure red cell aplasia, and rare anaphylactic reactions. Patients should be monitored closely for rapid hemoglobin rises, blood pressure changes, and any signs of allergic response.

Mircera is contraindicated in patients with known hypersensitivity to methoxy polyethylene glycol‑epoetin beta or any of its excipients, and in individuals with uncontrolled hypertension. It should also be used with caution in patients with a history of thromboembolic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methoxy Polyethylene Glycol-Epoetin Beta

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT